Peter Calabresi is using advanced imaging and biomedical and statistical tools to better tailor treatments for MS patients. "The more layers of complexity you understand,” he says, "the more you can fine-tune the therapy."

On March 28th, 2017, the United States Food and Drug Administration (FDA) announced the approval of Ocrevus (ocrelizumab) for the treatment of two types of multiple sclerosis (MS): relapsing forms of MS (RMS) and primary-progressive MS (PPMS).

Gary Pinder, who's living with MS, describes his approach to staying healthier with regular exercise. Read his tips on staying in motion, focusing on progress and connecting with others.

Researchers at Johns Hopkins University set out to understand why people with MS may be more susceptible to infections, especially in the lungs, than people without MS.

A recent cross-sectional study of RFI in a small cohort of relapsing remitting MS, performed by one of our study collaborators, revealed reductions in retinal arteriolar and venular blood flow velocities as compared to healthy controls.

The Intranasal Insulin research study primarily aims to evaluate the safety and tolerability of intranasal insulin in people with multiple sclerosis (MS). The secondary objective is to evaluate if intranasal insulin improves memory and learning in people with MS, as assessed by various neuropsychological tests.

Learn about the upcoming Rare Neuro-Immune Disorders Symposium on October 20th and 21st, 2017, in Columbus, Ohio.